drugset / Trial / NCT05787496
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
Timeline
- Start
- 2023-02-28
- Primary completion
- 2025-01-31
- Completion
- 2025-01-31
Outcome
Outcome not reported
Stopped: “As a result of program reprioritization and due to the limited clinical activity observed in the Phase 1 trial, the study has been discontinued.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NC525 | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | NC525 | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | NC525 | Monoclonal antibody | 4.5 mg/kg | Intravenous |
| Subject | NC525 | Monoclonal antibody | 9 mg/kg | Intravenous |
| Subject | NC525 | Monoclonal antibody | 13.5 mg/kg | Intravenous |
| Subject | NC525 | Monoclonal antibody | 18 mg/kg | Intravenous |